We are live on ! Find out more
BCYC

Bicycle Therapeutics

95 hedge funds and large institutions have $354M invested in Bicycle Therapeutics in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 30 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.62% less ownership

Funds ownership: 88.1%87.48% (-0.62%)

7% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 30

2% less funds holding

Funds holding: 9795 (-2)

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

40% less capital invested

Capital invested by funds: $586M → $354M (-$232M)

69% less call options, than puts

Call options by funds: $84K | Put options by funds: $269K

Holders
95
Holders Change
-2
Holders Change %
-2.06%
% of All Funds
1.27%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
15
Increased
28
Reduced
30
Closed
17
Calls
$84K
Puts
$269K
Net Calls
-$185K
Net Calls Change
-$77K
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$92.4M
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$31.3M -$10.2M -862,831 -19%
FIS
3
FCPM III Services
Netherlands
$29.3M
AC
4
Armistice Capital
New York
$22.7M +$5.61M +476,000 +22%
Westfield Capital Management
5
Westfield Capital Management
Massachusetts
$22.6M +$553K +46,968 +2%
SL
6
Siren LLC
Connecticut
$15.4M -$314K -26,646 -1%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$13M -$572K -48,543 -3%
LFCM
8
Long Focus Capital Management
Puerto Rico
$11M +$8.85M +750,661 +138%
BNP Paribas Asset Management
9
BNP Paribas Asset Management
France
$10.4M +$755K +64,037 +6%
CS
10
Candriam SCA
Luxembourg
$10.2M +$1.38M +117,331 +11%
RCM
11
RA Capital Management
Massachusetts
$9.28M
Morgan Stanley
12
Morgan Stanley
New York
$8.49M +$1.62M +137,700 +16%
EC
13
EcoR1 Capital
California
$7.73M
DTC
14
Deep Track Capital
Connecticut
$6.51M -$6M -509,065 -40%
Principal Financial Group
15
Principal Financial Group
Iowa
$5.36M +$2.65M +224,790 +55%
TCM
16
Tybourne Capital Management
Hong Kong
$4.89M -$8.17M -693,192 -55%
Bank of America
17
Bank of America
North Carolina
$4.78M +$2.01M +170,700 +43%
Axa
18
Axa
France
$4.7M -$3.26K -277 -0.1%
Millennium Management
19
Millennium Management
New York
$3.85M +$3.26M +276,671 +157%
JFG
20
Jefferies Financial Group
New York
$3.47M +$4.82M +408,889 New
WP
21
Woodline Partners
California
$3.09M +$4.29M +363,751 New
BlackRock
22
BlackRock
New York
$2.74M -$501K -42,532 -12%
Renaissance Technologies
23
Renaissance Technologies
New York
$2.56M +$377K +32,000 +12%
PIM
24
Platinum Investment Management
Australia
$2.44M -$253K -21,460 -7%
SAM
25
Silvercrest Asset Management
New York
$2.26M +$1.51M +127,953 +93%

BCYC Hedge Fund Activity: Q1 2025 in Review

95 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q1 2025, worth a combined $354M — down 40% from $586M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of BCYC and 15 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 28 added.

The largest buyer was Long Focus Capital Management, adding an estimated $8.85M. The largest seller was Point72 Asset Management, cutting an estimated $10.2M.

  • 95 institutional investors held Bicycle Therapeutics (BCYC) as of Q1 2025, down from 97 in Q4 2024.
  • Funds reported $354M of Bicycle Therapeutics stock for Q1 2025, down 40% quarter-over-quarter.
  • 15 funds opened new Bicycle Therapeutics positions in Q1 2025 and 17 closed out, a net change of -2 holders.
  • The largest Bicycle Therapeutics buyer in Q1 2025 was Long Focus Capital Management, an estimated $8.85M added.
  • The largest Bicycle Therapeutics seller in Q1 2025 was Point72 Asset Management, an estimated $10.2M sold.

Based on aggregated 13F filings for Q1 2025.